— Know what they know.
Not Investment Advice

GRAL

GRAIL, Inc.
1W: +8.0% 1M: +3.9% 3M: -44.6% YTD: -41.2% 1Y: +62.8%
$52.29
+3.64 (+7.48%)
After Hours: $49.95 (-2.34, -4.48%)
NASDAQ · Healthcare · Medical - Diagnostics & Research · $2.1B · Alpha Radar Strong Sell · Power 46
Smart Money Score
Bullish 75
Insider+$7.8M
Congress
ETF Holdings
Key Statistics
Market Cap$2.1B
52W Range20.44-118.84
Volume732,585
Avg Volume1,287,308
Beta5.21
Dividend
Analyst Ratings
3 Buy 1 Hold 0 Sell
Consensus Buy
Company Info
CEORobert Ragusa
Employees1,000
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2024-06-12
Websitegrail.com
1525 O’Brien Drive
Menlo Park, CA 94025
US
833-694-2553
About GRAIL, Inc.

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.

Recent Insider Trades

NameTypeSharesPriceDate
Freidin Aaron S-Sale 2,407 $47.93 2026-03-09
Freidin Aaron S-Sale 85 $46.74 2026-03-09
Ofman Joshua J. S-Sale 2,836 $47.93 2026-03-09
Ofman Joshua J. S-Sale 101 $46.74 2026-03-09
RAGUSA ROBERT P S-Sale 7,203 $47.93 2026-03-09

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms